Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 3;9:429–437. doi: 10.2147/OPTH.S78817

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Yoshikawa and Takahashi. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Response of choroidal osteoma to intravitreal injections of bevacizumab.

Notes: The left and right vertical axes in the graph represent LogMARvisual acuity (VA) and central foveal thickness, respectively. The horizontal axis is the time course from the initial visit. (A) In case 1, VA was temporarily decreased. However, at the final follow-up, the central foveal thickness was 181 μm and LogMAR VA was 0.15. VA remained unchanged at the final visit compared with the initial visit. (B) In case 2, central foveal thickness was decreased from 343 μm to 119 μm. LogMAR VA changed from 0.04 to 0.69. There were no data on the central foveal thickness before 54 months because we introduced spectral domain optical coherence tomography in our hospital in 2009. (C) In case 3, the central foveal thickness was 454 μm at the final visit. VA temporarily improved, but LogMAR VA changed from 0.09 to 1.00. Arrows denote intravitreal injections of bevacizumab.